225 related articles for article (PubMed ID: 32453797)
21. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
[TBL] [Abstract][Full Text] [Related]
22. Response to first line platinum-based chemotherapy in mismatch repair deficient (MMRd)/ microsatellite instability high (MSI-high) endometrial carcinoma.
Colomba E; Alexandre J; Le Teuff G; Genestie C; Coupez D; Coquard IR; Brachet PE; de Percin S; Sajous C; Fabbro M; Delanoy N; Joly F; Frenel JS; Pautier P; Leary A
Gynecol Oncol; 2023 Feb; 169():78-84. PubMed ID: 36521352
[TBL] [Abstract][Full Text] [Related]
23. Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study.
Hansen AR; Massard C; Ott PA; Haas NB; Lopez JS; Ejadi S; Wallmark JM; Keam B; Delord JP; Aggarwal R; Gould M; Yang P; Keefe SM; Piha-Paul SA
Ann Oncol; 2018 Aug; 29(8):1807-1813. PubMed ID: 29992241
[TBL] [Abstract][Full Text] [Related]
24. Pathological complete response with anti-PD-1 therapy in a patient with microsatellite instable high, BRAF mutant metastatic colon cancer: a case report and review of literature.
Sehdev A; Cramer HM; Ibrahim AA; Younger AE; O'Neil BH
Discov Med; 2016 May; 21(117):341-7. PubMed ID: 27355330
[TBL] [Abstract][Full Text] [Related]
25. Pantoprazole Affecting Docetaxel Resistance Pathways via Autophagy (PANDORA): Phase II Trial of High Dose Pantoprazole (Autophagy Inhibitor) with Docetaxel in Metastatic Castration-Resistant Prostate Cancer (mCRPC).
Hansen AR; Tannock IF; Templeton A; Chen E; Evans A; Knox J; Prawira A; Sridhar SS; Tan S; Vera-Badillo F; Wang L; Wouters BG; Joshua AM
Oncologist; 2019 Sep; 24(9):1188-1194. PubMed ID: 30952818
[TBL] [Abstract][Full Text] [Related]
26. An Emerging Landscape for Canonical and Actionable Molecular Alterations in Primary and Metastatic Prostate Cancer.
Dawson NA; Zibelman M; Lindsay T; Feldman RA; Saul M; Gatalica Z; Korn WM; Heath EI
Mol Cancer Ther; 2020 Jun; 19(6):1373-1382. PubMed ID: 32220973
[TBL] [Abstract][Full Text] [Related]
27. Predictors of Overall and Disease-Free Survival in Metastatic Castration-Resistant Prostate Cancer Patients Receiving
Sathekge M; Bruchertseifer F; Vorster M; Lawal IO; Knoesen O; Mahapane J; Davis C; Reyneke F; Maes A; Kratochwil C; Lengana T; Giesel FL; Van de Wiele C; Morgenstern A
J Nucl Med; 2020 Jan; 61(1):62-69. PubMed ID: 31101746
[TBL] [Abstract][Full Text] [Related]
28. Clinical implications of mismatch repair deficiency in prostate cancer.
Sedhom R; Antonarakis ES
Future Oncol; 2019 Jul; 15(20):2395-2411. PubMed ID: 31237441
[TBL] [Abstract][Full Text] [Related]
29. Genetic Testing in Prostate Cancer.
Sokolova AO; Cheng HH
Curr Oncol Rep; 2020 Jan; 22(1):5. PubMed ID: 31974718
[TBL] [Abstract][Full Text] [Related]
30. Synchronous metastatic gastric cancer-molecular background and clinical implications with special attention to mismatch repair deficiency.
Polom K; Böger C; Smyth E; Marrelli D; Behrens HM; Marano L; Becker T; Lordick F; Röcken C; Roviello F
Eur J Surg Oncol; 2018 May; 44(5):626-631. PubMed ID: 29545085
[TBL] [Abstract][Full Text] [Related]
31. Why is immunotherapy effective (or not) in patients with MSI/MMRD tumors?
Nebot-Bral L; Coutzac C; Kannouche PL; Chaput N
Bull Cancer; 2019 Feb; 106(2):105-113. PubMed ID: 30342749
[TBL] [Abstract][Full Text] [Related]
32. Genomic and clinical characterization of pulmonary-only metastatic prostate cancer: A unique molecular subtype.
Shenderov E; Isaacsson Velho P; Awan AH; Wang H; Mirkheshti N; Lotan TL; Carducci MA; Pardoll DM; Eisenberger MA; Antonarakis ES
Prostate; 2019 Sep; 79(13):1572-1579. PubMed ID: 31389628
[TBL] [Abstract][Full Text] [Related]
33. A retrospective, Canadian multi-center study examining the impact of prior response to abiraterone acetate on efficacy of docetaxel in metastatic castration-resistant prostate cancer.
Azad AA; Leibowitz-Amit R; Eigl BJ; Lester R; Wells JC; Murray RN; Kollmannsberger C; Heng DY; Joshua AM; Chi KN
Prostate; 2014 Nov; 74(15):1544-50. PubMed ID: 25175831
[TBL] [Abstract][Full Text] [Related]
34. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
Lavaud P; Gravis G; Foulon S; Joly F; Oudard S; Priou F; Latorzeff I; Mourey L; Soulié M; Delva R; Krakowski I; Laguerre B; Théodore C; Ferrero JM; Beuzeboc P; Habibian M; Rolland F; Deplanque G; Pouessel D; Zanetta S; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Tubiana-Mathieu N; Machiels JP; Kouri CE; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Culine S; Boher JM; Tergemina-Clain G; Legoupil C; Fizazi K
Eur Urol; 2018 May; 73(5):696-703. PubMed ID: 29074061
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of Radium-223 in Bone-metastatic Castration-resistant Prostate Cancer with and Without Homologous Repair Gene Defects.
Isaacsson Velho P; Qazi F; Hassan S; Carducci MA; Denmeade SR; Markowski MC; Thorek DL; DeWeese TL; Song DY; Tran PT; Eisenberger MA; Antonarakis ES
Eur Urol; 2019 Aug; 76(2):170-176. PubMed ID: 30293905
[TBL] [Abstract][Full Text] [Related]
36. Overcoming resistance to αPD-1 of MMR-deficient tumors with high tumor-induced neutrophils levels by combination of αCTLA-4 and αPD-1 blockers.
Nebot-Bral L; Hollebecque A; Yurchenko AA; de Forceville L; Danjou M; Jouniaux JM; Rosa RCA; Pouvelle C; Aoufouchi S; Vuagnat P; Smolenschi C; Colomba E; Leary A; Marabelle A; Scoazec JY; Cassard L; Nikolaev S; Chaput N; Kannouche P
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35896284
[TBL] [Abstract][Full Text] [Related]
37. Response to PD-1 Blockade in Microsatellite Stable Metastatic Colorectal Cancer Harboring a
Gong J; Wang C; Lee PP; Chu P; Fakih M
J Natl Compr Canc Netw; 2017 Feb; 15(2):142-147. PubMed ID: 28188185
[TBL] [Abstract][Full Text] [Related]
38. Successful immune checkpoint blockade in a patient with advanced stage microsatellite-unstable biliary tract cancer.
Czink E; Kloor M; Goeppert B; Fröhling S; Uhrig S; Weber TF; Meinel J; Sutter C; Weiss KH; Schirmacher P; Doeberitz MVK; Jäger D; Springfeld C
Cold Spring Harb Mol Case Stud; 2017 Sep; 3(5):. PubMed ID: 28619747
[TBL] [Abstract][Full Text] [Related]
39. Tumor mutation burden and checkpoint immunotherapy markers in primary and metastatic synovial sarcoma.
He M; Abro B; Kaushal M; Chen L; Chen T; Gondim M; Yan W; Neidich J; Dehner LP; Pfeifer JD
Hum Pathol; 2020 Jun; 100():15-23. PubMed ID: 32387103
[TBL] [Abstract][Full Text] [Related]
40. Intratumoural evolutionary landscape of high-risk prostate cancer: the PROGENY study of genomic and immune parameters.
Linch M; Goh G; Hiley C; Shanmugabavan Y; McGranahan N; Rowan A; Wong YNS; King H; Furness A; Freeman A; Linares J; Akarca A; Herrero J; Rosenthal R; Harder N; Schmidt G; Wilson GA; Birkbak NJ; Mitter R; Dentro S; Cathcart P; Arya M; Johnston E; Scott R; Hung M; Emberton M; Attard G; Szallasi Z; Punwani S; Quezada SA; Marafioti T; Gerlinger M; Ahmed HU; Swanton C
Ann Oncol; 2017 Oct; 28(10):2472-2480. PubMed ID: 28961847
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]